In UM, HDACi were able to reverse the adaptive survival mechanisms of increased YAP and AKT signaling after MEK inhibition, and combining a pan-HDAC inhibitor, panobinostat, with trametinib decreased tumor volume in animal models more than either drug alone (Faião-Flores et al., 2019). Here, MAP2K7 is linked to neoplasm.